BioXcel Therapeutics Appoints Vincent O’Neill Chief Medical Officer

Xconomy New York — 

Vincent O’Neill has been appointed senior vice president and chief medical officer of BioXcel Therapeutics (NASDAQ: BTAI). O’Neill had been serving as chief medical officer of the Branford, CT, company on a consulting basis since last July. His experience also includes senior roles at Genentech, Sanofi (NYSE: SNY), GlaxoSmithKline (NYSE: GSK), and Mirna Therapeutics. Earlier this year, BioXcel completed an IPO to finance clinical testing on a pair of drugs it found with the help of its artificial intelligence technology.